Tsurutani Y, et al. - A multicenter, randomized, prospective, open-label, active-controlled study was performed to evaluate the efficacy of ipragliflozin compared with sitagliptin in 124 Japanese subjects with type 2 diabetes. For the purpose of this investigation, sodium-glucose cotransporter 2 inhibitor and incretin-related agent naïve subjects were randomly assigned to receive additional 50 mg ipragliflozin or sitagliptin. It was observed that ipragliflozin had beneficial effects on fat reduction, insulin resistance, and lipid metabolism. On the other hand, sitagliptin had beneficial effects on β cell function.